Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICI’s Nolvadex

Executive Summary

Tamoxifen for the prevention of breast cancer is well tolerated in women at high risk for developing breast cancer, T.J. Powels, MD, Royal Marsden Hospital concluded in a presentation at the May 22 meeting of the American Society of Clinical Oncology. Because tamoxifen has demonstrated low toxicity, high compliance, and a lipid lowering profile in the 200-women pilot trial, a 10,000-patient multicenter trial is beginning enrollment in the U.K. and should be completed in the next two years, Powles said. Results of the pilot trial will be presented at the June 29 meeting of FDA's Oncologic Drugs Advisory Committee.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel